• 1
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 82741.
  • 2
    Kari S, Alho OP, Jokinen K, Hyrynkangas K, Läärä E. Carcinoma of the oral tongue in northern Finland: trends in overall incidence and patient and tumor characteristics. J Oral Pathol Med 1997; 26: 4803.
  • 3
    Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent 2001; 49: 7282.
  • 4
    Dickman PW, Hakulinen T, Luostarinen T, Pukkala E, Sankila R, Söderman B, Teppo L. Survival of cancer patients in Finland 1955–1994. Acta Oncol 1999; 38: 1103.
  • 5
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 126070.
  • 6
    Thomas GJ, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol 1999; 35: 22733.
  • 7
    Hong SD, Hong SP, Lee JI, Lim CY. Expression of metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to metastatic potential. Oral Oncol 2000; 36: 20713.
  • 8
    Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002; 95: 190210.
  • 9
    Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004; 10: 311016.
  • 10
    Juarez J, Clayman G, Nakajima M, Tanabe KK, Saya KK, Nicolson GL, Boyd D. Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in two invasive squamous cell carcinoma cell lines of the oral cavity. Int J Cancer 1993; 55: 1018.
  • 11
    Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004; 10: 63440.
  • 12
    Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 175763.
  • 13
    Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989; 58: 8035.
  • 14
    Itoh T, Tanioka M, Matsuda H, Nishomoto H, Yoshioka H, Suzuki R, Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999; 17: 17781.
  • 15
    Itoh T, Tanioka M, Yoshida H, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 104851.
  • 16
    Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 65772.
  • 17
    Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkilä P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999; 17: 76874.
  • 18
    Medina OP, Söderlund T, Laakkonen LJ, Tuominen EKJ, Koivunen E, Kinnunen P. Binding of novel inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res 2001; 61: 397885.
  • 19
    Valtanen H, Björklund M, Koivunen E. Method for designing peptides. Patent PCT/FI03/00705.
  • 20
    Björklund M, Valtanen H, Savilahti H, Koivunen E. Use of intein-directed peptide biosynthesis to improve serum stability and bioactivity of a gelatinase inhibitory peptide. Comb Chem High Throughput Screen 2003; 6: 2935.
  • 21
    Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, Tuuttila A, Niemi E, Teronen O, Heikkilä P, Tschesche H, Leinonen J, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 1997; 272: 2106774.
  • 22
    Risteli L, Risteli J. Analysis of extracellular matrix proteins in biological fluids. Methods Enzymol 1987; 145: 391411.
  • 23
    Mäkelä M, Salo T, Uitto VJ, Larjava HJ. Matrix metalloproteinases (MMP-2 and MMP-9) of the oral cavity: cellular origin and relationship to periodontal status. J Dent Res 1994; 73: 13971406.
  • 24
    Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, van Hinsbergh VWM, Helaakoski T, Kainulainen T, Rönkä H, Tschesche H, Salo T. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. J Biol Chem 1997; 272: 315049.
  • 25
    Heikkilä P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, van der Pluijm G, Baretlett JD, Salo T, Sorsa T. Bisphosphonates inhibit stromelysin-1 (MMP- 3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13: 24554.
  • 26
    Lewalle JM, Munaut C, Pichot B, Cataldo D, Baramova E, Foidart JM. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells. J Cell Physiol 1995; 165: 47583.
  • 27
    Pirilä E, Maisi P, Salo T, Koivunen E, Sorsa T. In vivo localization of gelatinases (MMP-2 and -9) by in situ zymography with a selective gelatinase inhibitor. Biochem Biophys Res Commun 2001; 287: 76674.
  • 28
    Mook ORF, Van Overbeek C, Ackema EG, Van Maldegam F, Frederiks WM. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 2003; 51: 8219.
  • 29
    Nyberg P, Heikkilä P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman U-H, Pihlajaniemi T, Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003; 278: 2240411.
  • 30
    Bancroft J, Stevens A. Theory and practice of histological techniques. New York: Churchill-Livingston, 1982. 1334.
  • 31
    Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. αVβ6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001; 92: 64150.
  • 32
    Brown P, Giavazzi R. Matrix metalloproteinase inhibition: a review of antitumor activity. Ann Oncol 1995; 6: 96774.
  • 33
    O-charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001; 127: 81320.
  • 34
    Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999; 21: 62738.
  • 35
    Yorioka CW, Coletta RD, Alves F, Nishimoto IN, Kowalski LP, Graner E. Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients. Int J Oncol 2002; 20: 18994.
  • 36
    Impola U, Uitto VJ, Hietanen J, Häkkinen L, Zhang L, Larjava H, Isaka K, Saarialho-Kere U. Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 2004; 202: 1422.
  • 37
    Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000; 17: 1099105.
  • 38
    Riedel F, Gotte K, Schwalb J, Hormann K. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res 2000; 20: 30459.
  • 39
    Baba Y, Tsukuda M, Mochimatsu I, Furukawa S, Kagata H, Nagashima Y, Koshika S, Imoto M, Kato Y. Inostamycin, an inhibitor of cytidine 5′-diphosphate1,2-diacyl-sn-glycerol (CD-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. Clin Exp Metastasis 2000; 18: 2739.
  • 40
    John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 1423.
  • 41
    Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA. Stromal matrix metalloproteinase-9 regulates vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004; 64: 167586.
  • 42
    Lasic DD, Ceh B, Stuart MC, Guo L, Frederik PM, Barenholz Y. Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta 1995; 1239: 14556.